CSL Stock Plummets to 8-Year Low on Profit Plunge

CSL Shares Tumble on Dismal Half-Year Results

CSL Ltd (ASX:CSL) shares plummeted to an eight-year low after the biotech firm announced a significant 81% drop in reported net profit for the first half. The decline was attributed to substantial one-off restructuring charges, asset impairments, and an unexpected change in CEO leadership.

Deep Dive into the Financials

For the six months ending December 31, CSL's reported net profit after tax fell to $401 million, while the underlying profit of $1.9 billion was down 7%. Total revenue saw a 4% decline to $8.3 billion on a constant currency basis, impacted by a 7% drop in CSL Behring sales due to policy reforms in the U.S. and China.

Factors Driving the Downturn and Market Reaction

The company booked approximately $1.1 billion in after-tax impairments, primarily linked to its Vifor and Seqirus units, citing increased generic competition. The market reacted sharply, with Sydney-listed shares falling as much as 12.4% to A$150.21. The news was compounded by the appointment of insider Gordon Naylor as interim CEO, replacing Paul McKenzie.

Company Outlook and Forward Guidance

Despite the weak first-half performance, CSL has maintained its full-year guidance. The company expressed confidence in second-half growth, which is expected to be driven by its immunoglobulin and albumin products, alongside new launches. To support shareholder value, CSL also expanded its share buyback program to $750 million.

FAQ

Q: Why did CSL's stock price drop so significantly?
A: The stock fell due to an 81% plunge in reported net profit, driven by $1.1 billion in impairments, restructuring costs, and a sudden change of CEO.

Q: What is CSL's outlook for the rest of the year?
A: CSL has maintained its full-year guidance and anticipates growth in the second half, supported by key products and an expanded $750 million share buyback program.

Source: Investing.com